[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

PH12018500694A1 - Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins - Google Patents

Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins

Info

Publication number
PH12018500694A1
PH12018500694A1 PH12018500694A PH12018500694A PH12018500694A1 PH 12018500694 A1 PH12018500694 A1 PH 12018500694A1 PH 12018500694 A PH12018500694 A PH 12018500694A PH 12018500694 A PH12018500694 A PH 12018500694A PH 12018500694 A1 PH12018500694 A1 PH 12018500694A1
Authority
PH
Philippines
Prior art keywords
type
compositions
methods
extracellular domains
chimeric proteins
Prior art date
Application number
PH12018500694A
Other languages
English (en)
Inventor
Taylor Schreiber
George Fromm
Silva Suresh De
Neal SCHILLING
Original Assignee
Heat Biologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Heat Biologics Inc filed Critical Heat Biologics Inc
Publication of PH12018500694A1 publication Critical patent/PH12018500694A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PH12018500694A 2015-10-01 2018-03-27 Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins PH12018500694A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562235727P 2015-10-01 2015-10-01
US201562263313P 2015-12-04 2015-12-04
US201662372574P 2016-08-09 2016-08-09
PCT/US2016/054598 WO2017059168A1 (fr) 2015-10-01 2016-09-30 Compositions et procédés pour le positionnement adjacent de domaines extracellulaires de type i et de type ii en tant que protéines chimériques hétérologues

Publications (1)

Publication Number Publication Date
PH12018500694A1 true PH12018500694A1 (en) 2018-10-01

Family

ID=58424302

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12018500694A PH12018500694A1 (en) 2015-10-01 2018-03-27 Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins

Country Status (17)

Country Link
US (13) US10183060B2 (fr)
EP (2) EP4183451A1 (fr)
JP (3) JP6981973B2 (fr)
KR (1) KR20180051651A (fr)
CN (3) CN108350055B (fr)
AU (3) AU2016331076B2 (fr)
BR (1) BR112018006578A2 (fr)
CA (1) CA2999280A1 (fr)
HK (1) HK1258835A1 (fr)
IL (3) IL258029B (fr)
MX (2) MX2018004022A (fr)
PH (1) PH12018500694A1 (fr)
RU (2) RU2022102624A (fr)
SA (1) SA518391219B1 (fr)
SG (5) SG10201913573UA (fr)
UA (1) UA126549C2 (fr)
WO (1) WO2017059168A1 (fr)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11998479B2 (en) 2011-02-04 2024-06-04 Seed Health, Inc. Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure
US11951140B2 (en) 2011-02-04 2024-04-09 Seed Health, Inc. Modulation of an individual's gut microbiome to address osteoporosis and bone disease
US10842834B2 (en) 2016-01-06 2020-11-24 Joseph E. Kovarik Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease
US11273187B2 (en) 2015-11-30 2022-03-15 Joseph E. Kovarik Method and system for reducing the likelihood of developing depression in an individual
US11951139B2 (en) 2015-11-30 2024-04-09 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US11844720B2 (en) 2011-02-04 2023-12-19 Seed Health, Inc. Method and system to reduce the likelihood of dental caries and halitosis
US10512661B2 (en) 2011-02-04 2019-12-24 Joseph E. Kovarik Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease
US11419903B2 (en) 2015-11-30 2022-08-23 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US10183069B2 (en) 2011-03-21 2019-01-22 Altimmune Inc. Rapid and prolonged immunologic-therapeutic
US11839632B2 (en) 2013-12-20 2023-12-12 Seed Health, Inc. Topical application of CRISPR-modified bacteria to treat acne vulgaris
US11969445B2 (en) 2013-12-20 2024-04-30 Seed Health, Inc. Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH
US11833177B2 (en) 2013-12-20 2023-12-05 Seed Health, Inc. Probiotic to enhance an individual's skin microbiome
US12005085B2 (en) 2013-12-20 2024-06-11 Seed Health, Inc. Probiotic method and composition for maintaining a healthy vaginal microbiome
US11998574B2 (en) 2013-12-20 2024-06-04 Seed Health, Inc. Method and system for modulating an individual's skin microbiome
US11980643B2 (en) 2013-12-20 2024-05-14 Seed Health, Inc. Method and system to modify an individual's gut-brain axis to provide neurocognitive protection
US11826388B2 (en) 2013-12-20 2023-11-28 Seed Health, Inc. Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation
CA2991628C (fr) 2015-07-16 2020-04-07 Bioxcel Therapeutics, Inc. Nouvelle approche pour le traitement du cancer par immunomodulation
US11566060B2 (en) 2017-01-05 2023-01-31 Kahr Medical Ltd. PD1-CD70 fusion protein and methods of use thereof
AU2018205888B2 (en) 2017-01-05 2021-09-02 Kahr Medical Ltd. A PD1-41BBL fusion protein and methods of use thereof
US11299530B2 (en) 2017-01-05 2022-04-12 Kahr Medical Ltd. SIRP alpha-CD70 fusion protein and methods of use thereof
SI3565828T1 (sl) 2017-01-05 2022-04-29 Kahr Medical Ltd. SIRP1 alfa-41BBL fuzijski protein in postopki za njegovo uporabo
SG11201906464UA (en) 2017-02-27 2019-08-27 Shattuck Labs Inc Csf1r-based chimeric proteins
EP3585410B9 (fr) * 2017-02-27 2023-10-04 Shattuck Labs, Inc. Protéines chimériques à base de vsig8
JP7128195B2 (ja) * 2017-02-27 2022-08-30 シャタック ラボ，インコーポレイテッド 細胞外ドメインベースのキメラタンパク質の製造方法及び使用方法
US20200048321A1 (en) * 2017-03-24 2020-02-13 Orpheus Bioscience Inc. Pantids for treatment of autoimmune disorders
KR20180120893A (ko) * 2017-04-28 2018-11-07 재단법인 목암생명과학연구소 Pvr 및 4-1bbl을 포함하는 융합단백질 및 이의 용도
AU2018306455A1 (en) * 2017-07-26 2020-02-27 Virogin Biotech Canada Ltd Oncolytic viral vectors and uses thereof
CN109646678A (zh) * 2017-10-12 2019-04-19 中国科学院上海生命科学研究院 Sun2蛋白、其制药用途及药物
CN108384795A (zh) * 2017-10-13 2018-08-10 江苏西迪尔生物技术有限公司 作用于tme免疫效应细胞的人工合成基因及验证方法和应用
JP7035299B2 (ja) * 2017-10-26 2022-03-15 イミューンオンコ バイオファーマシューティカルズ （シャンハイ） カンパニー リミテッド 新規組換融合タンパク質、ならびにその調製および使用
JP7339944B2 (ja) * 2017-11-07 2023-09-06 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム がんの処置におけるｃａｒ－ｔ細胞またはｃａｒ－ｎｋ細胞を用いるｌｉｌｒｂ４のターゲティング法
US20200407401A1 (en) * 2018-01-04 2020-12-31 Washington University Compositions and methods for inhibition of alphavirus infection
US11787870B2 (en) 2018-05-16 2023-10-17 Genome And Company Pharmaceutical composition for preventing or treating cancer comprising LRIT2 inhibitor as active ingredient
JP2021524282A (ja) * 2018-05-17 2021-09-13 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー ホスファターゼ動員による受容体の阻害
CA3103975A1 (fr) * 2018-06-21 2019-12-26 Shattuck Labs, Inc. Proteines heterodimeres et utilisations associees
EP3820887A4 (fr) * 2018-07-11 2022-04-20 KAHR Medical Ltd. Variant de la protéine de fusion pd1-4-1bbl et procédés d'utilisation associés
MX2021000263A (es) 2018-07-11 2021-05-12 Kahr Medical Ltd Proteina de fusion variante sirpalfa-4-1bbl y procedimientos de uso de la misma.
SG11202101429YA (en) 2018-08-23 2021-03-30 Seagen Inc Anti-tigit antibodies
MX2021002291A (es) * 2018-08-29 2021-05-27 Shattuck Labs Inc Terapias de combinacion que comprenden proteinas quimericas basadas en tim-3.
EP3843755A4 (fr) * 2018-08-29 2022-08-31 Shattuck Labs, Inc. Protéines chimériques à base de flt3l
US10780121B2 (en) 2018-08-29 2020-09-22 Shattuck Labs, Inc. FLT3L-based chimeric proteins
WO2020047329A1 (fr) * 2018-08-29 2020-03-05 Shattuck Labs, Inc. Protéines chimériques comprenant des domaines extracellulaires et leurs utilisations
KR20210068432A (ko) * 2018-08-29 2021-06-09 샤턱 랩스 인코포레이티드 병용 요법
AU2019327493A1 (en) * 2018-08-29 2021-03-04 Shattuck Labs, Inc. Combination therapies comprising sirp alpha-based chimeric proteins
CN109053902B (zh) * 2018-09-11 2021-06-15 河南科技大学 一种嵌合蛋白aqp4-ch2、制备及其应用
WO2020123477A1 (fr) * 2018-12-10 2020-06-18 Bioxcel Therapeutics, Inc. Traitements combinés pour traiter des maladies à l'aide d'un agent modifiant l'immunité innée et d'un agoniste de l'ox40
US20220025050A1 (en) * 2018-12-21 2022-01-27 Ose Immunotherapeutics Bifunctional molecule directed against human pd-1
KR20210113244A (ko) * 2019-01-07 2021-09-15 샤턱 랩스 인코포레이티드 감마 델타 t 세포를 조절하기 위한 이종이량체 단백질
US11098093B2 (en) * 2019-01-07 2021-08-24 Shattuck Labs, Inc. Heterodimeric proteins for modulating gamma delta T cells
WO2020142815A1 (fr) * 2019-01-07 2020-07-16 Celluris Participações Ltda Récepteur car bispécifique en tandem et procédé de modulation d'un microenvironnement tumoral
JP2022517226A (ja) * 2019-01-14 2022-03-07 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ がん免疫療法のためのｃｄ２００ａｒリガンド
CN111606999B (zh) * 2019-02-26 2022-09-06 南京惟亚德生物医药有限公司 兼具激活免疫共刺激信号通路和阻断免疫检查点的复制型溶瘤腺病毒及其应用
US20220185863A1 (en) * 2019-02-28 2022-06-16 Shattuck Labs, Inc. Combination therapies
WO2020232365A1 (fr) * 2019-05-16 2020-11-19 Shattuck Labs, Inc. Protéines chimériques dirigées par des cellules nk
CA3144071A1 (fr) * 2019-06-21 2020-12-24 Shattuck Labs, Inc. Lymphocytes t exprimant des proteines chimeriques
CN114375310A (zh) * 2019-07-11 2022-04-19 卡尔医学有限公司 数个异二聚体及其数个使用方法
WO2021041958A1 (fr) * 2019-08-30 2021-03-04 Shattuck Labs. Inc. Protéines chimériques utiles en auto-immunité
CN112480237B (zh) * 2019-09-12 2023-10-17 上海津曼特生物科技有限公司 一种融合蛋白及其制备方法和应用
CN110592172B (zh) * 2019-10-29 2021-05-28 华中农业大学 利用CRISPR/Cas9敲除文库技术筛选JEV抗性基因的方法与靶点
CN110964119A (zh) * 2019-12-05 2020-04-07 沣潮医药科技（上海）有限公司 抗疟二聚体免疫粘附素、药物组合物和用途
US20210230248A1 (en) * 2020-01-25 2021-07-29 Jun Chen Multivalent pharmacophores for high avidity and overexpressed-target specific binding and uses thereof
CN111826400A (zh) * 2020-07-21 2020-10-27 中科宝承生物医学科技有限公司 一种双特异性抗体nk细胞制备方法及其细胞和应用
CN111849913B (zh) * 2020-07-31 2021-05-25 南京北恒生物科技有限公司 工程化免疫细胞及其用途
CN116801897A (zh) * 2020-10-26 2023-09-22 沙塔克实验室有限公司 包含嗜乳脂蛋白的同二聚体和异二聚体蛋白
WO2022094482A1 (fr) * 2020-11-02 2022-05-05 Athae Bio, Inc. Protéines de fusion multimères à deux domaines
KR102671409B1 (ko) * 2021-03-02 2024-05-31 진화섭 Cd30을 발현하는 세포에 독성을 나타내는 재조합 단백질 및 이를 유효성분으로 포함하는 암의 치료용 약학적 조성물
WO2022187583A1 (fr) * 2021-03-05 2022-09-09 Shattuck Labs, Inc. Polythérapies faisant appel à des protéines chimériques à base de tim-3
IL305663A (en) * 2021-03-05 2023-11-01 Shattuck Labs Inc Combined treatments with SIRPa-based chimeric proteins
KR20220138909A (ko) * 2021-04-06 2022-10-14 주식회사 이뮤노로지컬디자이닝랩 Cd47에 특이적으로 결합하는 키메릭 항원 수용체 및 이의 용도
WO2023004424A2 (fr) * 2021-07-23 2023-01-26 University Of Southern California Exosomes multifonctionnels génétiquement modifiés pour l'immunothérapie
EP4384280A1 (fr) * 2021-08-12 2024-06-19 Baylor College of Medicine Récepteurs leurres solubles modifiés pour améliorer l'immunothérapie contre le cancer
MX2024007864A (es) * 2021-12-23 2024-09-06 Kahr Medical Ltd Polipeptidos lilrb y usos de los mismos.
KR20240135646A (ko) * 2022-01-20 2024-09-11 엑소큐어 스웨덴 에이비 막 단백질을 발현하는 재조합 세포주 및 이로부터 제조된 베지클
WO2024006931A1 (fr) * 2022-07-01 2024-01-04 Fate Therapeutics, Inc. Amélioration de la durabilité et de l'efficacité de cellules effectrices dans des thérapies cellulaires adoptives
CN117886891B (zh) * 2024-03-15 2024-06-07 黑龙江八一农垦大学 靶向巨噬细胞cd169受体的多肽及其应用

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
US5844095A (en) 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
ATE365209T1 (de) 1992-05-14 2007-07-15 Baylor College Medicine Mutierte steroidhormonrezeptoren, methoden für ihre benutzung und molekularer schalter für gentherapie
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US5674704A (en) * 1993-05-07 1997-10-07 Immunex Corporation Cytokine designated 4-IBB ligand
US6004941A (en) 1993-06-14 1999-12-21 Basf Aktiengesellschaft Methods for regulating gene expression
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
EP0770397B1 (fr) 1995-10-18 2004-04-21 Akzo Nobel N.V. Vaccin de combinaison contre la maladie de Newcastle
US6015709A (en) 1997-08-26 2000-01-18 Ariad Pharmaceuticals, Inc. Transcriptional activators, and compositions and uses related thereto
US5989910A (en) 1998-08-03 1999-11-23 University Of Lausanne Potent genetic switch allowing regulated gene expression in eukaryotic cells
US20110041190A1 (en) 2002-10-31 2011-02-17 Tykocinski Mark L Novel chimeric proteins
AU2926401A (en) 2000-01-03 2001-07-16 Tr Associates, L.L.C. Novel chimeric proteins and methods for using the same
US7696168B2 (en) 2000-04-21 2010-04-13 Tufts Medical Center, Inc. G protein coupled receptor agonists and antagonists and methods of activating and inhibiting G protein coupled receptors using the same
DE60143544D1 (de) 2000-12-12 2011-01-05 Medimmune Llc Moleküle mit längeren halbwertszeiten, zusammensetzungen und deren verwendung
JP4488740B2 (ja) * 2001-11-13 2010-06-23 ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド 免疫細胞活性化を調節する作用剤およびその使用方法
US7470428B2 (en) * 2002-01-30 2008-12-30 The Brigham And Women's Hospital, Inc. Compositions and methods related to TIM-3, a Th1-specific cell surface molecule
CN1798767B (zh) * 2003-04-10 2011-02-16 晶面生物技术公司 通过诱变来改变抗体对FcRn的结合亲和力或血清半衰期
MXPA06003686A (es) * 2003-10-03 2007-03-01 Brigham & Womens Hospital Ligandos tim-3 y sus metodos.
CA2512933C (fr) * 2003-11-13 2011-12-06 Hanmi Pharm. Ind. Co., Ltd. Composition pharmaceutique presentant une region de l'immunoglobuline fc comme excipient
US7459426B2 (en) * 2004-06-04 2008-12-02 Regeneron Pharmaceuticals, Inc. Methods of using IL-1 antagonists to treat autoinflammatory disease
US8802820B2 (en) * 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
JP2006345852A (ja) 2005-06-16 2006-12-28 Virxsys Corp 抗体複合体
US8008453B2 (en) * 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
CA2652570A1 (fr) 2006-05-15 2007-11-22 Viral Logic Systems Technology Corp. Compositions associees au cd47 et procedes destines au traitement de maladies et de troubles immunologiques
RU2487888C2 (ru) 2006-06-12 2013-07-20 ЭМЕРДЖЕНТ ПРОДАКТ ДИВЕЛОПМЕНТ СИЭТЛ, ЭлЭлСи Одноцепочечные мультивалентные связывающие белки с эффекторной функцией
EP2038303A2 (fr) * 2006-06-21 2009-03-25 Genentech, Inc. Structure cristalline du récepteur ox40l et ox40l complexé à ox40
US20100150931A1 (en) * 2006-11-22 2010-06-17 Centre Hospitalier De L'universite De Montreal Novel receptor for cd40l and uses thereof
ES2735144T3 (es) 2008-01-15 2019-12-16 Univ Leland Stanford Junior Métodos para manipular fagocitosis mediada por CD47
EP2262531A1 (fr) * 2008-03-08 2010-12-22 Immungene, Inc. Immunothérapie avec molécules de fusion modifiées utilisées dans le cancer et les maladies inflammatoires
CA3179151A1 (fr) * 2008-04-09 2009-10-15 Genentech, Inc. Compositions et procedes nouveaux pour le traitement de maladies de nature immunitaire
EP2111869A1 (fr) 2008-04-23 2009-10-28 Stichting Sanquin Bloedvoorziening Compositions et procédés pour renforcer le système immunitaire
JP5475766B2 (ja) 2008-06-30 2014-04-16 ユニバーシティ オブ ペンシルベニア Ｆｎ１４／ＴＲＡＩＬ融合タンパク質
CN102203258A (zh) 2008-07-02 2011-09-28 新兴产品开发西雅图有限公司 TGF-β拮抗剂多靶点结合蛋白
EP3281955A1 (fr) * 2008-10-02 2018-02-14 Aptevo Research and Development LLC Protéines de liaison multicibles antagonistes de cd86
US8183207B2 (en) 2008-11-26 2012-05-22 Five Prime Therapeutics, Inc. Treatment of osteolytic disorders and cancer using CSF1R extracellular domain fusion molecules
US8080246B2 (en) 2008-11-26 2011-12-20 Five Prime Therapeutics, Inc. Colony stimulating factor 1 receptor (CSF1R) extracellular domain fusion molecules
KR20110112299A (ko) * 2008-12-19 2011-10-12 노파르티스 아게 자가면역 및 염증성 장애의 치료에 사용하기 위한 가용성 폴리펩티드
ES2609333T3 (es) 2009-03-13 2017-04-19 The Trustees of The University of Pennsylvania-Center for Technology Transfer Proteínas de fusión OX40/TRAIL
ES2638521T5 (es) 2010-03-05 2021-03-02 Univ Johns Hopkins Composiciones y métodos para anticuerpos y proteínas de fusión inmunomoduladores dirigidos contra dianas
AU2011309689B2 (en) 2010-09-28 2015-01-15 Hadasit Medical Research Services & Development Ltd. Compositions and methods for treatment of hematological malignancies
EP2910572B1 (fr) 2010-11-11 2017-09-06 Versitech Limited Variants solubles pd-1, structures de fusion et utilisations de ceux-ci
LT2697257T (lt) * 2011-04-13 2016-12-27 Bristol-Myers Squibb Company Su fc sulieti baltymai, apimantys naujus linkerius ir išsidėstimus
US10179164B2 (en) 2011-05-25 2019-01-15 Cel-Sci Corporation Method for inducing an immune response for treatment of cancer and autoimmune diseases or conditions
CN102850458B (zh) 2011-06-28 2014-10-01 华博生物医药技术（上海）有限公司 新型重组双功能融合蛋白及其制法和用途
CN107266584B (zh) 2011-07-29 2022-05-13 宾夕法尼亚大学董事会 转换共刺激受体
ES2740358T3 (es) 2012-02-06 2020-02-05 Providence Health & Services Oregon Método de supervisión del tratamiento del cáncer con agonistas de OX40
CA2947354C (fr) 2012-04-30 2024-03-19 Biocon Limited Proteines de fusion ciblees/immunomodulatrices et leurs procedes de fabrication
ES2924722T3 (es) 2012-05-18 2022-10-10 Aptevo Res & Development Llc Unión de inmunofusión de scFv biespecífico (BIf) a CD123 y CD3
WO2013184912A2 (fr) 2012-06-06 2013-12-12 Oncomed Pharmaceuticals, Inc. Agents liants modulant la voie de signalisation hippo et leurs utilisations
CN112587658A (zh) 2012-07-18 2021-04-02 博笛生物科技有限公司 癌症的靶向免疫治疗
LT2931752T (lt) 2012-12-17 2019-12-10 Trillium Therapeutics Inc Ligos cd47+ ląstelių gydymas su sirp alfa-fc junginiais
AU2013371826A1 (en) 2013-01-01 2015-08-13 Kahr Medical Ltd. Stable form of signal converting protein fusion proteins, and methods of use and preparation thereof
US20140242077A1 (en) 2013-01-23 2014-08-28 Abbvie, Inc. Methods and compositions for modulating an immune response
WO2015116178A1 (fr) 2014-01-31 2015-08-06 Thomas Jefferson University Protéines de fusion pour la modulation des lymphocytes t régulateurs et effecteurs
US9873747B2 (en) 2013-01-31 2018-01-23 Thomas Jefferson University Fusion proteins that facilitate cancer cell destruction
EP2950814A4 (fr) 2013-01-31 2016-06-08 Univ Jefferson Protéines de fusion à base de pd-l1 et pd-l2 et leurs utilisations
US10533054B2 (en) 2013-01-31 2020-01-14 Thomas Jefferson University Agonist fusion protein for CD40 and OX40 and methods of stimulating the immune system
EP2951199A4 (fr) 2013-01-31 2016-07-20 Univ Jefferson Protéines de fusion pour la modulation des lymphocytes t régulateurs et effecteurs
WO2014134165A1 (fr) * 2013-02-26 2014-09-04 Memorial Sloan-Kettering Cancer Center Compositions et procédés d'immunothérapie
DK2970512T3 (en) 2013-03-12 2019-01-14 Biocon Ltd IMMUNO MODULATOR FUSION PROTEINS AND PROCEDURES FOR PRODUCING THEREOF
CA2924172C (fr) * 2013-09-13 2020-06-30 Beigene, Ltd. Anticorps anti-pd1 et leur utilisation comme produits therapeutiques et produits de diagnostic
CA2927756A1 (fr) * 2013-10-15 2015-04-23 Novo Nordisk Health Care Ag Polypeptides du facteur vii de la coagulation
US10144770B2 (en) 2013-10-17 2018-12-04 National University Of Singapore Chimeric receptors and uses thereof in immune therapy
US10196435B2 (en) 2013-11-18 2019-02-05 University Of Southern California OX40L fusion protein for the immunotherapy of tumors of veterinary animals
CN105899535A (zh) * 2013-12-17 2016-08-24 豪夫迈·罗氏有限公司 用pd-1轴结合拮抗剂和抗cd20抗体治疗癌症的方法
AU2014364606A1 (en) 2013-12-17 2016-07-07 Genentech, Inc. Combination therapy comprising OX40 binding agonists and PD-1 axis binding antagonists
EP3094650A2 (fr) 2014-01-13 2016-11-23 Pieris Pharmaceuticals GmbH Polypeptide multi-spécifique utilisé pour l'immunomodulation tumorale localisée
US20170015758A1 (en) 2014-01-21 2017-01-19 Medimmune, Llc Compositions And Methods For Modulating And Redirecting Immune Responses
GB201403875D0 (en) * 2014-03-05 2014-04-16 Cantargia Ab Novel antibodies and uses thereof
EP3122783B1 (fr) * 2014-03-24 2019-09-04 Immuneonco Biopharmaceuticals (Shanghai) Co., Ltd. Nouvelles protéines de fusion bifonctionnelles recombinées, leur préparation et leur utilisation
US9718870B2 (en) 2014-05-29 2017-08-01 Medimmune, Llc OX40L fusion proteins and uses thereof
EP3160497A4 (fr) 2014-06-27 2018-01-17 H. Lee Moffitt Cancer Center And Research Institute, Inc. Conjugués pour immunothérapie
TWI759810B (zh) 2014-08-08 2022-04-01 美商Ａｌｘ腫瘤技術股份有限公司 信號調節蛋白α(signal-regulatory proteinα, SIRP-α)變體構築物及其用途
PL3482766T3 (pl) 2014-08-11 2020-11-16 Delinia, Inc. Modyfikowane warianty il-2, które selektywnie aktywują limfocyty t regulatorowe do leczenia chorób autoimmunologicznych
RU2017108203A (ru) 2014-08-15 2018-09-17 Мерк Патент Гмбх Слитые белки sirp-альфа с иммуноглобулином
US20160166685A1 (en) 2014-11-17 2016-06-16 Genentech, Inc. Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
WO2016090347A1 (fr) 2014-12-05 2016-06-09 Immunext, Inc. Identification de vsig8 en tant que récepteur putatif de vista et son utilisation pour produire des modulateurs de vista/vsig8
SG11201706024YA (en) * 2015-01-26 2017-08-30 Macrogenics Inc Multivalent molecules comprising dr5-binding domains
US11161907B2 (en) 2015-02-02 2021-11-02 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
MA41460A (fr) 2015-02-03 2017-12-12 Oncomed Pharm Inc Agents de liaison à la tnfrsf et leurs utilisations
BR112017016681A2 (pt) 2015-02-06 2018-04-10 Heat Biologics Inc vetor de coexpressão de vacina e moléculas coestimulatórias
WO2016166139A1 (fr) 2015-04-14 2016-10-20 Eberhard Karls Universität Tübingen Protéines de fusion bispécifiques pour augmenter les réponses immunitaires de lymphocytes contre des cellules tumorales
CA2994935A1 (fr) 2015-05-18 2016-11-24 Ab Initio Biotherapeutics, Inc. Compositions de polypeptide sirp et procedes d'utilisation
CN117964732A (zh) 2015-08-07 2024-05-03 Alx肿瘤生物技术公司 具有SIRP-α结构域或其变体的构建体
WO2018075960A1 (fr) 2016-10-21 2018-04-26 Tioma Therapeutics, Inc. Anticorps cd47 thérapeutiques

Also Published As

Publication number Publication date
EP4183451A1 (fr) 2023-05-24
CN116063567A (zh) 2023-05-05
US10660936B2 (en) 2020-05-26
US20180125935A1 (en) 2018-05-10
US20200261537A1 (en) 2020-08-20
AU2021200367C1 (en) 2024-05-30
IL258029A (en) 2018-05-31
US20200246431A1 (en) 2020-08-06
KR20180051651A (ko) 2018-05-16
US20180326005A1 (en) 2018-11-15
US20180326008A1 (en) 2018-11-15
BR112018006578A2 (pt) 2018-12-26
IL258029B (en) 2022-09-01
MX2018004022A (es) 2018-09-11
IL295423B1 (en) 2023-07-01
IL303586B1 (en) 2024-11-01
UA126549C2 (uk) 2022-11-02
AU2016331076A1 (en) 2018-04-05
AU2021200367B2 (en) 2024-05-02
CN116063566A (zh) 2023-05-05
SG10201913597VA (en) 2020-02-27
US10653748B2 (en) 2020-05-19
US20180326006A1 (en) 2018-11-15
US10188701B2 (en) 2019-01-29
IL303586A (en) 2023-08-01
US20180064787A1 (en) 2018-03-08
US11654180B2 (en) 2023-05-23
CN108350055B (zh) 2022-11-08
US10646545B2 (en) 2020-05-12
JP7303254B2 (ja) 2023-07-04
AU2024202253A1 (en) 2024-05-16
AU2021200367A1 (en) 2021-03-18
JP2021168699A (ja) 2021-10-28
CA2999280A1 (fr) 2017-04-06
US10493128B2 (en) 2019-12-03
IL295423A (en) 2022-10-01
MX2022001299A (es) 2022-05-10
CN108350055A (zh) 2018-07-31
JP6981973B2 (ja) 2021-12-17
US20180326007A1 (en) 2018-11-15
RU2766200C1 (ru) 2022-02-09
US10525102B2 (en) 2020-01-07
AU2016331076B2 (en) 2020-12-03
US11547742B1 (en) 2023-01-10
EP3356393A4 (fr) 2019-08-07
RU2022102624A (ru) 2022-03-10
JP2023112132A (ja) 2023-08-10
US20200101136A1 (en) 2020-04-02
US20190151413A1 (en) 2019-05-23
HK1258835A1 (zh) 2019-11-22
US10449233B2 (en) 2019-10-22
US20170095531A1 (en) 2017-04-06
IL295423B2 (en) 2023-11-01
US10543253B2 (en) 2020-01-28
SA518391219B1 (ar) 2022-11-30
US10086042B2 (en) 2018-10-02
JP2018529363A (ja) 2018-10-11
SG10201913591SA (en) 2020-02-27
US10183060B2 (en) 2019-01-22
US20180326004A1 (en) 2018-11-15
SG11201801984TA (en) 2018-04-27
SG10201913573UA (en) 2020-03-30
EP3356393A1 (fr) 2018-08-08
SG10201913576RA (en) 2020-02-27
WO2017059168A1 (fr) 2017-04-06

Similar Documents

Publication Publication Date Title
MX2022001299A (es) Composiciones y métodos para unir dominios extracelulares de tipo i y tipo ii como proteínas quiméricas heterólogas.
ZA201905488B (en) Tigit- and light-based chimeric proteins
ZA201901924B (en) Anti¿lag¿3 antibodies and compositions
MX2020014031A (es) Proteinas heterodimericas y usos de las mismas.
PH12018500711A1 (en) Anti-pd1 antibodies and methods of use
PH12019500923A1 (en) Anti-pd-1 antibodies and compositions
PH12017501483A1 (en) Bicyclic heterocycles as fgfr4 inhibitors
ZA201801852B (en) Anti¿pd¿1 antibodies and compositions
SA517381703B1 (ar) C10orf54 - أجسام مضادة لـ واستخداماتها
EP4421094A3 (fr) Agents thérapeutiques ciblés et leurs utilisation
PH12016501644A1 (en) Binding proteins and methods of use thereof
PH12016501441A1 (en) Chimeric alkaline phosphate-like proteins
JO3791B1 (ar) تركيبات و طرق الأجسام المضادة المستهدفة لـ bmp6
PH12018501279A1 (en) Compositions comprising 15-hepe and methods of using the same
PH12019501534A1 (en) Csf1r-based chimeric proteins
MX2017015690A (es) Anticuerpos dirigidos a la proteina morfogenetica osea 9 (bmp9) y metodos a partir de estos.
MY180844A (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
SG10201805646WA (en) Angiopoietin-like 4 antibodies and methods of use
MX2021002294A (es) Terapias de combinacion que comprenden proteinas quimericas basadas en pd-1.
MX2021002289A (es) Proteinas quimericas basadas en flt3l.
EP4249503A3 (fr) Protéines chimériques à base de vsig8
MX2021002286A (es) Terapias de combinacion.
MX2018007468A (es) Composiciones de colageno 7 y metodos para usar las mismas.
MX2017003949A (es) Derivados peptidicos novedosos y sus usos.